Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)

Abstract

The negative symptoms of schizophrenia are an unmet treatment target as currently approved treatments mostly control positive symptoms. The persistence of these symptoms holds back the patient's reinstatement in society, making them incapable of fulfilling their social, professional, or family roles. There is overwhelming research evidence suggesting that the negative symptoms of schizophrenia are associated with poorer functioning and lower quality of life than positive symptoms, confirming the need for developing new treatments for this particular category of symptoms. This present review aims to review clinical trials addressing novel pharmacological approaches addressing primary negative symptoms of schizophrenia. We overview both monotherapies, first-generation and second-generation antipsychotics, and add-on therapies, including psychostimulants, anti-inflammatory drugs, antidepressants, molecules targeting glutamatergic, cholinergic or serotonergic systems and hormones. Our findings suggest that the primary negative symptoms of schizophrenia may be mitigated by adjunctive therapies, and we highlight the pharmacological agents that have proven superior efficacy. Novel compounds such as cariprazine and MIN-101, to date, show promising results, but large clinical trials are needed to test their efficacy and safety.

1. Introduction

Negative symptoms have long been recognized as a core feature of schizophrenia since the first description of the disease and remain unmet treatment targets. Even though negative symptoms represent a heterogeneous syndrome, there is now a consensus regarding its constitutive factors, which encompass blunted affect, alogia, social withdrawal, avolition, and anhedonia (1). An important distinction has been made in the last decades between primary and secondary negative symptoms. The primary ones are considered to be intrinsic to the disease. Secondary ones are the result of other categories of symptoms such as positive symptoms, depressive symptoms, cognitive deficits, extrapyramidal side effects, or social deprivation or chronic consumptive disorders. Unlike primary negative symptoms, which are not adequately targeted by current interventions, secondary negative symptoms respond to treatment of the underlying cause (2,3).

There are several reasons why there is a growing interest in developing treatments, specifically targeting primary negative symptoms. First, negative symptoms of schizophrenia are a significant contributor to poor functional outcomes and low quality of life to a greater extent than positive symptoms (4-6). The high prevalence of these symptoms was demonstrated by an epidemiological study conducted by Bobes et al in 2010, which established a prevalence rate of approximately 58%, for at least one primary negative symptom in patients diagnosed with schizophrenia (7). The lack of approved treatments for this group of symptoms emerges from the fact that no treatment has been proven effective and reliable from large clinical trials (5,8).

2. Literature review methodology

The present review aims to provide a general overview of the recent research into pharmacological treatment approaches targeting negative symptoms of schizophrenia. This is a selective review of the literature published between 1998 and 2019. We decided to focus on this period, as many advances have been achieved to treat negative symptoms. Moreover, during this period, research attention shifted from the positive to the negative symptoms of schizophrenia. The following databases PubMed, Web of Science and Elsevier were searched, using the following combinations of terms: ‘Negative symptoms in schizophrenia’, AND ‘antipsychotic treatment’, ‘antidepressant treatment’, ‘cholinergic’, ‘glutamate’, ‘hormones’, to identify clinical trials designed for the pharmacological treatment of primary negative symptoms. We included only clinical trials, reviews, and meta-analyses, published in English, on human subjects, which used clinically validated scales for schizophrenia and negative symptoms (e.g., Positive and Negative Syndrome Scale, Brief Negative Symptoms Scale or Negative Symptoms assessment Scale-16) and which differentiated between primary, secondary negative symptoms.

We focused only on compounds targeting the dopaminergic system, the glutamate system, the serotonergic system, the cholinergic system, or the inflammatory pathway and hormones, which have been tested as potential treatments for primary negative symptoms (Table I).

Table I.

Clinical trials evaluating pharmacological compounds targeting negative symptoms in schizophrenia.

Neurotransmitter system	Study, year	Agent	Mechanism	Duration (weeks)	No. of subjects	Negative symptom instrument	Findings	(Refs.)
Dopamine system	Buchanan et al, 1998	Clozapine	D2, 5-HT2A antagonist	10 + extension 1 year	75	SANS	No benefit PNS	(10)
	Liang and Yu, 2017	Amisulpride	Partial agonist D2/D3, antagonist 5-HT7	8	26	PANSS	Efficient for NS/SNS	(14)
	Potkin et al, 2013	Asenapine	D2, 5HT2A α2 adrenoceptors antagonist	25 + additional 52	502	PANSS, NSA-16	Efficient for NS	(21)
	Fleischhacker et al, 2019	Cariprazine	D2/D3, 5-HT1A partial agonist	26	227	PANSS	Efficient for PNS	(22)
Glutamate system	Umbricht et al, 2014	Bitopertin	Glycine reuptake inhibitor	8	323	PANSS	Efficient for NS	(28)
	Mazinani et al, 2017	Memantine	NMDA receptor antagonist	12	46	PANSS	Efficient for PNS	(30)
Inflammatory pathway	Laan et al, 2010	Aspirin	Anti-inflammatory drug	36	70	PANSS	No benefit for PNS	(36)
	Zang et al, 2018	Minocyclin	Tetracycline	12	75	PANSS	Efficient for NS	(44)
	Sepehrmanesh et al, 2018	NAC	Anti-inflammatory and glutamatergic excitotoxicity	12	84	PANSS	Efficient for PNS	(42)
Serotonin system	Davidson et al, 2017	MIN-101	5-HT2A antagonist	12	244	PANSS, BNSS	Efficient for PNS	(49)
	Samadi et al, 2017	Ondansetron	5-HT3 antagonist	12	38	PANSS	Efficient for PNS	(47)
Cholinergic system	Conley et al, 2009	Galantamine	Acetylcholinesterase inhibitor	12	84	SANS	Efficient for alogia	(60)
Hormones	Modabbernia et al, 2013	Oxytocin		8	37	PANSS	No benefit PNS	(66)

D2, dopamine D2 receptors; 5-HT, 5 hydroxytryptamine receptors; NMDA, N-methyl-D-aspartate; NAC, N-acetylcysteine. PANSS, Positive and Negative Syndrome Scale. NSA-16, Negative Symptoms Assessment Scale-16 items. SANS, Scale for the Assessment of Negative Symptoms. BNSS, Brief Negative Symptom Scale. PNS, primary negative symptoms. NS, negative symptoms. SNS, secondary negative symptoms.

3. The dopamine system

First-generation antipsychotics

First-generation antipsychotics include chlorpromazine, fluphenazine, haloperidol, and their mechanism of action is based on blocking D2 dopamine receptors. Even though it was thought that these drugs ameliorate negative symptoms, further research has shown that the improvements appeared only in secondary negative symptoms as a result of the improvements in positive symptoms (9).

Atypical antipsychotics

Second-generation antipsychotics, also known as atypical antipsychotics (AA) were introduced in the late 1980s, and they were thought to be a significant breakthrough in the treatment of negative symptoms, due to their heterogeneous mechanism of action. In addition to the blocking in various degrees of D2 dopamine receptors, they possess a wide variety of affinities for other neurotransmitter receptors. While initially second-generation antipsychotics appeared to be more efficacious than first-generation antipsychotics in treating primary negative symptoms, well-conducted meta-analyses showed that their efficacy was attributable to changes in secondary negative symptoms (2,8). They were found to have fewer extrapyramidal side effects and, additionally, they have antidepressant properties related to their affinity for serotonergic receptors.

Two second-generation antipsychotics, amisulpride and clozapine, were believed to have a superior effect on negative symptoms than other atypical antipsychotics. The limitations found for many trials evaluating clozapine's efficacy for negative symptoms were given by the fact that the symptoms were evaluated globally and were not divided in primary and secondary (2,3). A study worth mentioning from 1998 conducted by Buchanan et al (10), categorized the sample of patients in deficit or non-deficit schizophrenia, and evaluated the response to clozapine for each group. The results showed that the apparent benefit of clozapine for treating negative symptoms arises from its greater efficacy in treating positive symptoms, and, therefore, only secondary negative symptoms benefit from clozapine treatment with the disadvantage of overweight which could lead to depression and self-stigmatization (11). Other meta-analyses and well-designed clinical trials support these findings (9,12,13). Amisulpride, another second-generation antipsychotic, was approved in some European countries for the treatment of negative symptoms, because of its high affinity for dopamine D2 and D3 receptors and low affinity for 5-HT1A, 5-HT2A receptors. Amisulpride has received particular attention, but even though the first results were encouraging, meta-analyses revealed that the apparent benefits in improving negative symptoms were attributable to its ability to ameliorate depressed mood (2,14,15).

The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study was designed in 2000 to compare typical vs. atypical antipsychotics' efficacy. Contrary to the study hypothesis, the efficacy of the two generations of antipsychotics was similar, except for olanzapine. In addition, there were no significant differences regarding negative symptomatology, except for olanzapine, which showed better effects than all the other agents (16). These results were also supported by studies conducted by Pilla Redy et al (17) and Shafti and Gilanipoor (18), emphasizing the superiority of olanzapine and its antidepressant effects.

Asenapine is an atypical antipsychotic antagonist of various dopaminergic, serotonergic, and α adrenergic receptors, and it has an appreciably high affinity for 5HT2A receptors than D2 receptors. However, its antagonism of α2 adrenoceptors is believed to improve negative symptoms and cognitive function in schizophrenia (19). A phase 2 efficacy study suggested that asenapine was superior to risperidone in decreasing negative symptoms in schizophrenia at six weeks (20). Another clinical trial comparing olanzapine and asenapine showed no significant difference over 26 weeks but indicated superiority for asenapine with continued treatment for 52 weeks (21).

A novel antipsychotic drug cariprazine, which is a dopamine D3/D2 receptor partial agonist, D3-preferring, and serotonin 5-HT1A receptor partial agonist, showed its efficacy in a prospectively designed trial targeting persistent, predominant negative symptoms in patients with schizophrenia in comparison to risperidone (22). We found another two randomized, double-blind, placebo- and active-controlled studies in patients with acute schizophrenia and moderate/severe negative symptoms, in which cariprazine was associated with significant improvement in negative symptoms compared with aripiprazole and placebo (23).

Psychostimulants

Clinical evidence suggests that psychostimulants, dopamine agonists, can induce psychotic symptoms in healthy individuals and exacerbate them in schizophrenic patients. However, it has also been suggested that these agents could manage negative symptoms due to their ability to stimulate the dopamine mesocortical pathway (8). A study from 2013 examined the efficacy of lisdexamfetamine dimesylate as adjunctive therapy to antipsychotics and showed a significant improvement in negative symptomatology, but other clinical trials did not support these findings (24,25).

4. Glutamatergic pathway

Deficient signaling through the N-methyl-D-aspartate (NMDA) receptor is hypothesized to underlie many signs and symptoms associated with schizophrenia, in particular negative symptoms. Glycine acts as a co-agonist NMDA receptor. The most studied agents include D-cycloserine and glycine, which target the glycine site of NMDA receptors as partial agonists, but the results were inconsistent across trials (8,9,26). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST) was the most significant trial testing D-cycloserine and glycine antipsychotic-adjunctive therapy. In this trial, the placebo's efficacy was comparable to treatment, even though there were reported effects in some patient subpopulations (3,27). The blockade of the glycine transporter type 1 inhibits glycine reuptake, and through this elevates synaptic glycine concentrations. This led to the hypothesis that it can be an effective strategy to enhance NMDA receptor transmission. Bitopertin is a glycine reuptake inhibitor; its efficacy and tolerability were evaluated in patients with schizophrenia and predominantly negative symptoms, who were stable while taking an antipsychotic treatment in several studies (28,29). However, an only small improvement was associated with bitopertin, and this taken together with the varying placebo response, purported the conclusion that adjunctive bitopertin treatment offers only modest benefit (29).

Various studies have aimed to test the efficacy of memantine, a weak NMDA receptor antagonist, in treating negative symptoms. The results of these trials were encouraging, as 20 mg of memantine as add-on therapy to risperidone (30,31) or clozapine (32) significantly improved negative symptoms. A meta-analysis from 2017 focused on memantine add-on to antipsychotic treatment for negative and cognitive symptoms of schizophrenia and concluded that it might be beneficial, especially for negative symptoms. However, it also underlined that the negative-symptom effect size might be associated with younger age in schizophrenia patients (33).

Preclinical and clinical data show that pregnenolone, a neurosteroid, and an anti-inflammatory drug could potentially mitigate GABA dysregulation and/or NMDA receptor hypofunction in patients with schizophrenia via the metabolism of other neurosteroids. An 8-week, pregnenolone add-on therapy to antipsychotic medications, placebo-controlled trial reported a reduction in the severity of negative symptoms in recent-onset schizophrenia if it was not used in conjunction with mood stabilizers (34).

5. The inflammatory pathway

Accumulating evidence shows that anti-inflammatory drugs may play an important role in schizophrenia, as a propensity towards a pro-inflammatory status in the brain of patients with schizophrenia is widely accepted. Additionally, it has been suggested that higher levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-α are related to negative symptoms, mainly flat affect (35). Some of the examined anti-inflammatory agents include aspirin, celecoxib, bexarotene, omega-3 fatty acids, pregnenolone, N-acetylcysteine (NAC), minocycline, bexarotene, davunetide, dextromethorphan, melatonin, minocycline, statins, varenicline, and Withania somnifera extract (36,37). A meta-analysis from 2019, which included 56 studies indicated that the following compounds: Bexarotene, celecoxib, davunetide, dextromethorphan, fatty acids, pregnenolone, statins, and varenicline showed no significant effect and the agents with significant effect in at least two studies were aspirin, minocycline, and NAC (38).

The effects of aspirin as an adjunct treatment for schizophrenia were also reviewed in 2019 by Schmidt and colleagues. However, it was impossible to conclude because the evidence produced by the trials was weak, therefore inconclusive (39).

The association between schizophrenia with mitochondrial abnormalities, glutathione deficit, and increased brain oxidative stress has been reported in several studies. The potential benefit of the antioxidant and anti-inflammatory capacity and mitigation of glutamatergic excitotoxicity of NAC was investigated in several clinical trials for its benefits regarding negative symptoms, with inconsistent results (40-42). A randomized, multicenter, double-blind, placebo-controlled study, published in 2008 by Berk et al evaluating the safety and efficacy of NAC in chronic schizophrenia, reported that NAC was less efficacious than placebo after eight weeks, but produced significant reductions in Positive and Negative Syndrome Scale (PANSS) negative, general, and total scores vs. placebo after 24 weeks (43).

The efficacy of minocycline, a second-generation tetracycline, was assessed as adjunctive therapy to risperidone and showed a significant improvement in negative symptoms of schizophrenia in a 3-month, double-blind, randomized, placebo-controlled clinical trial. The proposed potential mechanism underlying its efficacy was the reduction in pro-inflammatory cytokines (44). A comprehensive meta-analysis conducted in 2014 examining minocycline, as add-on therapy, in patients with schizophrenia receiving antipsychotic agents, reported its superiority, compared to a placebo, in improving the general psychopathology of schizophrenia, especially negative symptoms (45).

6. Serotonin system

Serotonin (5-HT) 3 receptor antagonists are widely used to prevent nausea and vomiting, mostly in patients receiving chemotherapy for cancer. Small studies have suggested that this class of medication could be useful as an adjunct therapy to alleviate the cognitive and negative symptoms of schizophrenia (46,47). A meta-analysis including three tropisetron plus risperidone studies, one ondansetron plus risperidone study, one ondansetron plus haloperidol, and granisetron plus risperidone study, all selective 5-HT3 receptor antagonist, used in schizophrenia stable patients revealed their beneficial effect on the psychopathology, especially negative symptoms when compared to controls. Also, the add-on selective 5-TH3 receptor antagonists seemed to be well-tolerated treatments (48).

MIN-101 is a new compound with affinities for 5-HT2A and sigma-2 receptors and no direct dopamine affinities, which demonstrated efficacy in reducing negative symptoms in stable schizophrenia patients compared to a placebo (49).

Antidepressants have been widely used in clinical trials targeting negative symptoms, but the major methodological limitation in evaluating their efficacy is the difficulty to distinguish between improvements in primary negative symptoms vs. the ones secondary to depression. Two major meta-analyses evaluated antidepressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, tetracyclic antidepressants, mirtazapine vs. placebo antipsychotic add-on therapy for negative symptoms (50,51). Both indicated a significant benefit, but with a medium overall size effect. Some authors recommend antidepressants in addition to antipsychotics in treatment for schizophrenia in patients with persistent negative symptoms (52). Although most studies report improvement for negative symptoms with combined antidepressant/antipsychotic treatment [mirtazapine/olanzapine (53), mirtazapine/risperidone (54), escitalopram/aripiprazole (55)], other studies did not replicate these findings (56,57). Most clinical trials evaluated either serotonin selective reuptake inhibitors or mirtazapine, but one recent study indicated that duloxetine seems to be a tolerable and efficacious agent, as an adjuvant to risperidone, for primary negative symptoms of schizophrenia (58). A randomized controlled trial reported another interesting finding on treatment-resistant schizophrenia patients augmented with escitalopram, which found an improvement in persistent negative symptoms and decreased IL-6 and C-reactive protein (59).

7. Cholinergic system

The cholinergic system is composed of muscarinic and nicotinic receptors, which both use acetylcholine as a neurotransmitter. The cholinergic model for schizophrenia suggests that the alterations of the acetylcholine signaling system and the decrease in muscarinic and nicotinic receptors may contribute to the development of cognitive and negative symptoms. In addition, the observations that high doses of anticholinergic drugs can induce psychotic symptoms supports this theory (8,52). Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine), currently used for dementia, have been studied as a potential treatment for negative symptoms, as they increase cholinergic activity (60). Two meta-analyses examined the effects of cholinergic agents as adjunctive therapies targeting negative symptoms. The results showed that acetylcholinesterase inhibitors may have benefits in the treatment of negative symptoms (61,62).

8. Hormones

The endocrine model for schizophrenia has been proposed because of the gender differences in illness onset and course, given the lower age of onset in men and the higher prevalence of onset in premenopausal women. It has been hypothesized that estrogen has a protective role. Several studies have evaluated the role of estrogen as an antipsychotic add-on therapy for negative symptoms, in both women and men, with promising results (63,64). However, a quantitative review on estrogen augmentation in schizophrenia, which included only double-blind, placebo-controlled, randomized studies, reported that estrogen, especially estradiol, could be an effective augmentation strategy, but only in women with schizophrenia (65).

Oxytocin, a neuropeptide known to moderate social behaviors, has been investigated as a potential therapeutic compound for negative symptoms of schizophrenia in recent years (66). A systematic review and meta-analysis of randomized controlled trials comparing oxytocin augmentation therapy with placebo in patients with schizophrenia, published in 2016, indicated that oxytocin was superior to placebo for decreasing the PANSS general subscale scores. However, there were no differences from placebo in total, positive, or negative symptoms scores. However, a sensitivity analysis, which included oxytocin administration on consecutive day studies, did support its superior efficacy compared to placebo in negative symptoms (67).

9. Conclusions

In this study, we reviewed some of the potentially effective therapeutic agents that have been considered for the treatment of negative symptoms of schizophrenia, and we attempted to provide a general overview. However, given the extent of this topic, we must mention that we highlighted only the most investigated mechanisms of action and that other drugs that we have not mentioned are being actively explored.

In the last few decades, clinicians have started placing more emphasis on managing the negative symptoms of schizophrenia as these symptoms are poorly managed by current treatments and account for the impaired functioning and low quality of life of these patients.

Although the initial excitement surrounding the breakthrough in second-generation antipsychotics for treating negative symptoms has disappeared, there is some evidence that certain second-generation antipsychotics (olanzapine, clozapine, amisulpride and asenapine) may confer benefits in treating negative symptoms. However, it is difficult to distinguish whether these improvements are related only to secondary negative symptoms.

Newer compounds targeting primary negative symptoms, cariprazine, and MIN-101, have shown promising results, but more extensive clinical trials are needed to consolidate these findings.

Several antipsychotic add-on therapies (cholinergic, glutamatergic and serotonergic agents, anti-inflammatory drugs and hormones) are currently under investigation. However, the results in these areas are still controversial due to the low number of trials and to issues arising from trial design (short duration, small sample size, variable definitions for negative symptoms, trials not designed for primary negative symptoms); thus, more clinical trials are needed to establish the efficacy for these treatments.

Significant progress has been made in the last decade in defining negative symptoms, distinguishing between primary and secondary negative symptoms, and quantifying negative symptoms, but despite this progress, there are still few clinical trials that focus predominantly on negative symptoms. Some of the proposed directions for future research follow a proper methodology for measuring persistent negative symptoms in clinical trials and identifying different biomarkers that define subgroups of patients with negative symptoms and try to find a common mechanism of action in these subpopulations.

Funding

No funding was received.

Availability of data and materials

All information in this review was documented by relevant references.

Authors' contributions

OOC, IVM and MFS designed the review. OOC and MFS performed the literature search, selection of articles and wrote the paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.